Type of Therapy and Quality of Life in Atrial Fibrillation

  • B. Lüderitz
Conference paper


Atrial fibrillation (AF) is a frequent and costly health care problem. In patients with AF, the restoration and maintenance of sinus rhythm is the primary therapeutic goal. The most frequent strategy for maintaining sinus rhythm after its restoration is the use of antiarrhythmic drugs. The efficacy of therapy in AF has been predominantly measured using objective criteria such as mortality and morbidity. In recent years, the importance of quality of life as an outcome measure has been recognized. However, few studies in the literature have examined quality of life in patients with AF using properly validated tools. In addition, the specific impact of antiarrhythmic treatment on quality of life in patients with AF has not been assessed. These issues are now being addressed in several ongoing studies. This article attempts to define quality of life, makes recommendations on how quality of life might be assessed, and reviews our current knowledge regarding quality of life in patients with AF.


Atrial Fibrillation Sinus Rhythm Chronic Atrial Fibrillation Global Life Satisfaction Maintain Sinus Rhythm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG (1995) Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 155:469–473PubMedCrossRefGoogle Scholar
  2. 2.
    Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA (1994) Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 271:840–844PubMedCrossRefGoogle Scholar
  3. 3.
    Kannel WB, Wolf PA, Benjamin EJ, Levy D (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82:2N–9NPubMedCrossRefGoogle Scholar
  4. 4.
    Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE (1995) The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 98:476–484PubMedCrossRefGoogle Scholar
  5. 5.
    Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–952PubMedCrossRefGoogle Scholar
  6. 6.
    Luderitz B, Jung W (2000) Quality of life in patients with atrial fibrillation. Arch Intern Med 160:1749–1757PubMedCrossRefGoogle Scholar
  7. 7.
    Jung W, Luderitz B (1998) Quality of life in patients with atrial fibrillation. J Cardiovasc Electrophysiol 9 [Suppl 8]:5177–5186Google Scholar
  8. 8.
    Crijns HJGM, Van Gelder IC, Tieleman RG, Gosselink ATM, Van den Berg MP (1997) Why is atrial fibrillation bad for you? In: Murgatroyd FD, Camm AJ (eds) Nonpharmacological management of atrial fibrillation. Futura, Armonk, pp 3–13Google Scholar
  9. 9.
    Schumacher B, Luderitz B (1998) Rate issues in atrial fibrillation: consequences of tachycardia and therapy for rate control. Am J Cardiol 82:29N–36NPubMedCrossRefGoogle Scholar
  10. 10.
    Lönnerholm S, Blomström P, Nilsson L, Oxelbark S, Jideus L, Blomström-Lundqvist C (2000) Effects of the Maze operation on health-related quality of life in patients with atrial fibrillation. Circulation 101:2607–2611PubMedCrossRefGoogle Scholar
  11. 11.
    Wellens JJW, Lau CP, Luderitz B, Akhtar M, Waldo A, Camm AJ, Timmermans C, Tse HF, Jung W, Jordaens L, Ayers G, for the METRIX Investigators (1998) Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation 98:1651–1656Google Scholar
  12. 12.
    Luderitz B, Jung W (2000) Quality of life in atrial fibrillation. J Intery Card Electrophysiol 4:201–209CrossRefGoogle Scholar
  13. 13.
    Savelieva I, Paquette M, Dorian P, Luderitz B, Camm AJ (2001) Quality of life in patients with silent atrial fibrillation. Heart 85:216–217PubMedCrossRefGoogle Scholar
  14. 14.
    Wyse DG (2000) The AFFIRM trial: main trial and substudies - what can we expect? J Intery Card Electrophysiol 4:171–176CrossRefGoogle Scholar
  15. 15.
    Heinz G, Siostrzonek P, Kreiner G, Gossinger H (1992) Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol 69:489–492PubMedCrossRefGoogle Scholar
  16. 16.
    Twidale N, Sutton K, Bartlett L, Booley A, Winstanley S, Heddle W, Hassam R, Koutsounis H (1993) Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias. Pacing Clin Electrophysiol 16:1275–1284PubMedCrossRefGoogle Scholar
  17. 17.
    Rodriguez LM, Smeets JL, Xie B, de Chillou C, Cherix E, Pieters F, Metzger J, den Dulk K, Wellens HJJ (1993) Improvement in left ventricular function by ablation of atrio-ventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 72:1137–1141PubMedCrossRefGoogle Scholar
  18. 18.
    Brignole M, Gionfranchi L, Menozzi C, Bottoni N, Bollini R, Lolli G, Oddone D, Giaggioli G (1994) Influence of atrioventricular junction radiofrequency ablation patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 74:242–246PubMedCrossRefGoogle Scholar
  19. 19.
    Edner M, Caidahl K, Bergfeldt L, Darpö B, Edvardsson N. Rosenqvist M (1995) Prospective study of left ventricular function after radiofrequency ablation of atrio-ventricular junction in patients with atrial fibrillation. Br Heart J 74:261–267PubMedCrossRefGoogle Scholar
  20. 20.
    Fitzpatrick AP, Kourouyan HD, Siu A, Lee RJ, Lesh MD, Epstein LM, Griffin JC, Scheinman NM (1996) Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 131:499–507PubMedCrossRefGoogle Scholar
  21. 21.
    Natale A, Zimerman L, Tomassoni G, Kearney M, Kent V, Brandon MJ, Newby K (1996) Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cardiol 78:1431–1433PubMedCrossRefGoogle Scholar
  22. 22.
    Steinbeck G (1996) Drug therapy of atrial fibrillation: control of heart rate versus establishing sinus rhythm (in German). Z Kardiol 85[Suppl 61:69–74Google Scholar
  23. 23.
    Bathina MN, Mickelsen S, Brooks C, Jaramillo J, Hepton T, Kusumoto FM (1998) Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. Am J Cardiol 82:589–593PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • B. Lüderitz
    • 1
  1. 1.Department of Cardiology, Faculty of MedicineUniversity of BonnGermany

Personalised recommendations